Details of the Drug
General Information of Drug (ID: DMHHP50)
| Drug Name |
Cantuzumab mertansine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Cantuzumab ravtansine; Cantuzumab ravtansine); HuC242-DM1; HuC242-DM4; IMGN-242; L-DM4; Modified cantuzumab mertansine, ImmunoGen; SB-408075; SB-40875; Ansamitocin-anticolon Ab conjugate, ImmunoGen/GlaxoSmithKline; Ansamitocin-anticolon Ab conjugate, ImmunoGen/SmithKline Beecham; DM1-anticolon Ab conjugate, ImmunoGen/GSK; DM1-anticolon Ab conjugate, ImmunoGen/GlaxoSmithKline; DM1-anticolon Ab conjugate, ImmunoGen/SmithKline Beecham
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Monoclonal antibody
|
||||||||||||||||||||||
| Structure | 3D Structure is Not Available |
 |
|||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||